Increased Urine IgM and IgG(2) Levels, Indicating Decreased Glomerular Size Selectivity, Are Not Affected by Dalteparin Therapy in Patients with Type 2 Diabetes

Overview

Journal Biochem Res Int

Publisher Wiley

Specialty Biochemistry

Date 2012 Mar 9

PMID 22400116

Citations 1

Authors

Ole Torffvit

Majid Kalani

Jan Apelqvist

Bjorn Eliasson

Jan W Eriksson

Kerstin Brismar

Gun Jorneskog

Affiliations

Soon will be listed here.

Abstract

Fifty-four type 2 diabetic patients with neuroischemic foot ulcers were randomised to treatment with 5000 IU of dalteparin, (n = 28), or physiological saline, (n = 26), once daily until ulcer healing or for a maximum of 6 months. Thirty-three patients had normo-, 15 micro-, and 6 macroalbuminuria. The urinary levels of IgM and IgG(2) were elevated in 47 and 50 patients, respectively. Elevated urinary levels of IgM and IgG(2) indicate decreased glomerular size selectivity. Urine IgM levels were associated with IGF-1/IGFBP-1 and IGFBP-1 levels. Dalteparin treatment increased urinary levels of glycosaminoglycans (P < 0.001) and serum IGFBP-1 (P < 0.05) while no significant effects were seen in any of the other studied parameters. In conclusion, dalteparin therapy in patients with type 2 diabetes had no effects on urinary levels of albumin, IgM, or IgG(2) despite significantly increased glycosaminoglycans in urine. Elevated urinary levels of IgM and IgG(2) might be more sensitive markers of renal disease than albuminuria in patients with type 2 diabetes and antihypertensive therapy.

Citing Articles

Urinary biomarkers for early diabetic nephropathy in type 2 diabetic patients.

Fiseha T Biomark Res. 2015; 3:16.

PMID: 26146561 PMC: 4491239. DOI: 10.1186/s40364-015-0042-3.

References

Chiba Y, Tani N, Yamazaki M, Nakamura H, Ito S, Shibata A . Glomerular charge selectivity in non-insulin-dependent diabetes mellitus. J Diabet Complications. 1991; 5(2-3):135-7. DOI: 10.1016/0891-6632(91)90046-r. View

Marshall S, Hansen K, Osterby R, Frystyk J, Orskov H, Flyvbjerg A . Effects of heparin on renal morphology and albuminuria in experimental diabetes. Am J Physiol. 1996; 271(2 Pt 1):E326-32. DOI: 10.1152/ajpendo.1996.271.2.E326. View

Tamsma J, van den Born J, Bruijn J, Assmann K, Weening J, Berden J . Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparan sulphate in the glomerular basement membrane. Diabetologia. 1994; 37(3):313-20. DOI: 10.1007/BF00398060. View

Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A . Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia. 1989; 32(4):219-26. DOI: 10.1007/BF00285287. View

Bakoush O, Tencer J, Tapia J, Rippe B, Torffvit O . Higher urinary IgM excretion in type 2 diabetic nephropathy compared to type 1 diabetic nephropathy. Kidney Int. 2002; 61(1):203-8. DOI: 10.1046/j.1523-1755.2002.00108.x. View

Kalani M, Silveira A, Blomback M, Apelqvist J, Eliasson B, Eriksson J . Beneficial effects of dalteparin on haemostatic function and local tissue oxygenation in patients with diabetes, severe vascular disease and foot ulcers. Thromb Res. 2007; 120(5):653-61. DOI: 10.1016/j.thromres.2006.12.006. View

Nielsen S, Schmitz A, Bacher T, Rehling M, Ingerslev J, Mogensen C . Transcapillary escape rate and albuminuria in Type II diabetes. Effects of short-term treatment with low-molecular weight heparin. Diabetologia. 1999; 42(1):60-7. DOI: 10.1007/s001250051114. View

Torffvit O, Rippe B . Size and charge selectivity of the glomerular filter in patients with insulin-dependent diabetes mellitus: urinary immunoglobulins and glycosaminoglycans. Nephron. 1999; 83(4):301-7. DOI: 10.1159/000045421. View

Stephens R, McElduff P, Heald A, New J, Worthington J, Ollier W . Polymorphisms in IGF-binding protein 1 are associated with impaired renal function in type 2 diabetes. Diabetes. 2005; 54(12):3547-53. DOI: 10.2337/diabetes.54.12.3547. View

10.

Goode N, Shires M, Crellin D, Aparicio S, Davison A . Alterations of glomerular basement membrane charge and structure in diabetic nephropathy. Diabetologia. 1995; 38(12):1455-65. DOI: 10.1007/BF00400607. View

11.

Gambaro G, Kinalska I, Oksa A, Pontuch P, Hertlova M, Olsovsky J . Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol. 2002; 13(6):1615-25. DOI: 10.1097/01.asn.0000014254.87188.e5. View

12.

Unden A, Elofsson S, Brismar K . Gender differences in the relation of insulin-like growth factor binding protein-1 to cardiovascular risk factors: a population-based study. Clin Endocrinol (Oxf). 2005; 63(1):94-102. DOI: 10.1111/j.1365-2265.2005.02306.x. View

13.

Yoshioka K, Imanishi M, Konishi Y, Sato T, Tanaka S, Kimura G . Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients. Diabetes Care. 1998; 21(4):482-6. DOI: 10.2337/diacare.21.4.482. View

14.

Sharma K, Ziyadeh F, Alzahabi B, McGowan T, Kapoor S, Kurnik B . Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes. 1997; 46(5):854-9. DOI: 10.2337/diab.46.5.854. View

15.

van der Pijl J, van der Woude F, Geelhoed-Duijvestijn P, Frolich M, van der Meer F, Lemkes H . Danaparoid sodium lowers proteinuria in diabetic nephropathy. J Am Soc Nephrol. 1997; 8(3):456-62. DOI: 10.1681/ASN.V83456. View

16.

Tamsma J, van der Woude F, Lemkes H . Effect of sulphated glycosaminoglycans on albuminuria in patients with overt diabetic (type 1) nephropathy. Nephrol Dial Transplant. 1996; 11(1):182-5. View

17.

Vasylyeva T, Ferry Jr R . Novel roles of the IGF-IGFBP axis in etiopathophysiology of diabetic nephropathy. Diabetes Res Clin Pract. 2006; 76(2):177-86. PMC: 1892792. DOI: 10.1016/j.diabres.2006.09.012. View

18.

Lewis E, Lewis J, Greene T, Hunsicker L, Berl T, Pohl M . Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis. 2011; 58(5):729-36. DOI: 10.1053/j.ajkd.2011.06.020. View

19.

Ichikawa I, Yoshida Y, Fogo A, PURKERSON M, KLAHR S . Effect of heparin on the glomerular structure and function of remnant nephrons. Kidney Int. 1988; 34(5):638-44. DOI: 10.1038/ki.1988.228. View

20.

Chaudhary K, Phadke G, Nistala R, Weidmeyer C, McFarlane S, Whaley-Connell A . The emerging role of biomarkers in diabetic and hypertensive chronic kidney disease. Curr Diab Rep. 2010; 10(1):37-42. DOI: 10.1007/s11892-009-0080-z. View